Gyre Therapeutics (GYRE) Competitors

Gyre Therapeutics logo
$4.56 +0.17 (+3.87%)
Closing price 04:00 PM Eastern
Extended Trading
$4.55 -0.01 (-0.22%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GYRE vs. PBH, HRMY, ETON, ANIP, and RAPP

Should you buy Gyre Therapeutics stock or one of its competitors? Gyre Therapeutics's main competitors and comparable companies include Prestige Consumer Healthcare (PBH), Harmony Biosciences (HRMY), Eton Pharmaceuticals (ETON), ANI Pharmaceuticals (ANIP), and Rapport Therapeutics (RAPP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Gyre Therapeutics compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Gyre Therapeutics had 1 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 3 mentions for Gyre Therapeutics and 2 mentions for Prestige Consumer Healthcare. Gyre Therapeutics' average media sentiment score of 0.60 beat Prestige Consumer Healthcare's score of 0.25 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prestige Consumer Healthcare
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gyre Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Prestige Consumer Healthcare has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

Prestige Consumer Healthcare currently has a consensus target price of $67.00, suggesting a potential upside of 37.93%. Given Prestige Consumer Healthcare's stronger consensus rating and higher possible upside, equities analysts plainly believe Prestige Consumer Healthcare is more favorable than Gyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Gyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Prestige Consumer Healthcare has a net margin of 13.29% compared to Gyre Therapeutics' net margin of -14.80%. Prestige Consumer Healthcare's return on equity of 11.28% beat Gyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Prestige Consumer Healthcare13.29% 11.28% 5.25%
Gyre Therapeutics -14.80%-7.39%-5.74%

Prestige Consumer Healthcare has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$1.09B2.11$190.30M$3.2414.99
Gyre Therapeutics$110.06M4.74$5.03M-$0.20N/A

Summary

Prestige Consumer Healthcare beats Gyre Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Harmony Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Gyre Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

Harmony Biosciences currently has a consensus price target of $48.00, indicating a potential upside of 46.16%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Harmony Biosciences is more favorable than Gyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38
Gyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Harmony Biosciences has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony Biosciences$868.45M2.22$158.69M$3.0210.87
Gyre Therapeutics$110.06M4.74$5.03M-$0.20N/A

In the previous week, Harmony Biosciences had 13 more articles in the media than Gyre Therapeutics. MarketBeat recorded 16 mentions for Harmony Biosciences and 3 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.60 beat Harmony Biosciences' score of 0.33 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harmony Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Gyre Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Harmony Biosciences has a net margin of 18.05% compared to Gyre Therapeutics' net margin of -14.80%. Harmony Biosciences' return on equity of 18.55% beat Gyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Harmony Biosciences18.05% 18.55% 13.24%
Gyre Therapeutics -14.80%-7.39%-5.74%

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Harmony Biosciences beats Gyre Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Eton Pharmaceuticals?

Gyre Therapeutics (NASDAQ:GYRE) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Eton Pharmaceuticals had 15 more articles in the media than Gyre Therapeutics. MarketBeat recorded 18 mentions for Eton Pharmaceuticals and 3 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.60 beat Eton Pharmaceuticals' score of 0.49 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gyre Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eton Pharmaceuticals
6 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Gyre Therapeutics has higher revenue and earnings than Eton Pharmaceuticals. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gyre Therapeutics$110.06M4.74$5.03M-$0.20N/A
Eton Pharmaceuticals$79.95M23.14-$4.60M$1.5142.49

Eton Pharmaceuticals has a consensus price target of $79.75, indicating a potential upside of 24.30%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Gyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Eton Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Eton Pharmaceuticals has a net margin of 35.35% compared to Gyre Therapeutics' net margin of -14.80%. Eton Pharmaceuticals' return on equity of 104.82% beat Gyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gyre Therapeutics-14.80% -7.39% -5.74%
Eton Pharmaceuticals 35.35%104.82%43.09%

Gyre Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Summary

Eton Pharmaceuticals beats Gyre Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Gyre Therapeutics. MarketBeat recorded 5 mentions for ANI Pharmaceuticals and 3 mentions for Gyre Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Gyre Therapeutics' score of 0.60 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ANI Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Gyre Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ANI Pharmaceuticals presently has a consensus target price of $100.00, suggesting a potential upside of 41.22%. Given ANI Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe ANI Pharmaceuticals is more favorable than Gyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43
Gyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

ANI Pharmaceuticals has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANI Pharmaceuticals$883.37M1.82$78.34M$5.0214.11
Gyre Therapeutics$110.06M4.74$5.03M-$0.20N/A

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ANI Pharmaceuticals has a net margin of 11.22% compared to Gyre Therapeutics' net margin of -14.80%. ANI Pharmaceuticals' return on equity of 28.34% beat Gyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals11.22% 28.34% 11.18%
Gyre Therapeutics -14.80%-7.39%-5.74%

ANI Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

Summary

ANI Pharmaceuticals beats Gyre Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Rapport Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Rapport Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -14.80%. Gyre Therapeutics' return on equity of -7.39% beat Rapport Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gyre Therapeutics-14.80% -7.39% -5.74%
Rapport Therapeutics N/A -34.00%-31.89%

Gyre Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

In the previous week, Gyre Therapeutics had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 3 mentions for Gyre Therapeutics and 2 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.35 beat Gyre Therapeutics' score of 0.60 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gyre Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rapport Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Gyre Therapeutics has higher revenue and earnings than Rapport Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gyre Therapeutics$110.06M4.74$5.03M-$0.20N/A
Rapport TherapeuticsN/AN/A-$111.48M-$3.17N/A

24.0% of Gyre Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rapport Therapeutics has a consensus target price of $64.50, indicating a potential upside of 168.81%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Gyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Rapport Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

Summary

Gyre Therapeutics and Rapport Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Gyre Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GYRE vs. The Competition

MetricGyre TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$525.86M$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E Ratio-22.8029.4134.1729.85
Price / Sales4.787.028.485.62
Price / Cash19.3515.7421.9322.50
Price / Book3.655.114.373.66
Net Income$5.03M$2.88B$3.52B$392.27M
7 Day Performance7.80%-4.11%-5.47%-4.72%
1 Month Performance-25.00%-5.09%-4.58%-7.14%
1 Year Performance-43.14%-7.45%-1.79%-7.51%

Gyre Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GYRE
Gyre Therapeutics
0.6329 of 5 stars
$4.56
+3.9%
N/A-45.1%$525.86M$110.06MN/A618
PBH
Prestige Consumer Healthcare
3.2317 of 5 stars
$44.93
+2.9%
$67.00
+49.1%
-20.0%$2.07B$1.09B9.75890
HRMY
Harmony Biosciences
4.3799 of 5 stars
$33.55
-0.7%
$48.00
+43.1%
-3.1%$1.98B$868.45M11.19293
ETON
Eton Pharmaceuticals
3.9388 of 5 stars
$67.54
+5.0%
$79.75
+18.1%
+276.8%$1.86B$79.95M44.7344
ANIP
ANI Pharmaceuticals
3.6471 of 5 stars
$71.25
+5.1%
$100.00
+40.4%
-15.6%$1.56B$883.37M14.19970

Related Companies and Tools


This page (NASDAQ:GYRE) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners